FOLH1 and prostate cancer: Additionally, compared with 68Ga-PSMA-11, the standard-of-care PET tracer for prostate cancer, 68Ga-MY6349 PET/CT demonstrated comparable lesion uptake and a better TBR for imaging primary and metastatic lesions, resulting in the visualization of more metastatic lesions, especially for the occult bone metastases.